Flare Therapeutics is a clinical-stage biotech developing small-molecule drugs that target transcription factors, including a first-in-class ARON-targeting degrader for prostate cancer.

Japanese pharmaceutical company developing prescription drugs, infectious disease therapies, and specialty medicines, including a former sleep apnea drug joint venture with Apnimed.